Skip to content

Liposomal bupivacaine for adductor canal block in total knee arthroplasty: a randomized, parallel-controlled, single-center clinical trial

Liposomal bupivacaine for adductor canal block in total knee arthroplasty: a randomized, parallel-controlled, single-center clinical trial

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500106286
Enrollment
Unknown
Registered
2025-07-22
Start date
2025-07-28
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Interventions

Experimental Group:Preoperative adductor duct block was performed using bupivacaine liposomes
Control group:Preoperative adductor canal block with ropivacaine

Sponsors

the First Hospital of Jilin University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients who undergo unilateral knee replacement for the first time due to osteoarthritis; 2. ASA classification I - III; 3. Age >=18 years old; 4. The patient voluntarily participated in this study, understood the research procedures and methods, and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Patients with abnormal anatomical structures of the adductor ducts and cryptonerves on the same side due to various reasons, or those suffering from other peripheral neuropathy, such as diabetic peripheral neuropathy, multiple sclerosis, nerve root lesions, or those with a history of trauma surgery on the affected limb and incomplete recovery after treatment; 2.Patients who had a new myocardial infarction or unstable angina pectoris 6 months ago; 3. People allergic to amide local anesthetics; 4. Patients with concurrent mental disorders and cognitive dysfunction; 5.Patients who underwent contralateral knee joint replacement 6 months ago; 6. Having any other disease can increase the risk for patients after using nerve block.

Design outcomes

Primary

MeasureTime frame
numerical rating scale;

Secondary

MeasureTime frame
Measurement of quality of recovery-40;

Countries

China

Contacts

Public ContactLiu Huanqiu

The First Hospital of Jilin University

liuhq@jlu.edu.cn+86 138 0446 3426

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026